Cargando…
Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
The increasing incidence of inflammatory bowel disease (IBD) globally has redirected the healthcare system's focus towards safe and affordable pharmacological interventions. The inception of anti-tumor necrosis factor-α (TNF-α) had resulted in a trend shift from surgical interventions. However,...
Autores principales: | Najeeb, Hala, Yasmin, Farah, Surani, Salim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125297/ https://www.ncbi.nlm.nih.gov/pubmed/35663066 http://dx.doi.org/10.12998/wjcc.v10.i14.4327 |
Ejemplares similares
-
Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022) -
Novel drug delivery systems for inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022) -
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018) -
Electrical neuromodulation therapy for inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022) -
Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)